Medline (MDLN) - Compounder or PE Dump?

Medline (MDLN) IPO'd in Dec 2025. It was a previous LBO and PE is now looking for an exit. The structure is... complicated. **tl;dr:** Great business (huge moat, sticky customers), but the governance is a "Controlled Company" nightmare. PE firms still pull the strings, and management incentives are tied to Adjusted EBITDA and debt paydown rather than ROIC (shareholder value). Medline is listing as a **"Controlled Company."** * The Mills family and the PE Consortium (Blackstone, Carlyle, Hellman & Friedman) control **>60%** of the voting power. * Because they have >50%, Medline is **exempt** from Nasdaq rules requiring a majority independent board. They are also exempt from having independent compensation or nominating committees. * Minority shareholders have effectively zero say. The Board answers to the PE firms, not shareholders. The Board is a "Who's Who" of Private Equity. It is not an independent oversight body; it’s a committee of the owners. * **The Family:** Charlie Mills (Chair) and Andy Mills are still very involved. This provides good cultural continuity but also means the family dynasty is still in charge. * **The PE Heavies:** * **Joe Baratta (Blackstone)** \- Global Head of Private Equity. * **Steve Wise (Carlyle)** \- Global Head of Healthcare. * **Jake Best (Hellman & Friedman)** \- Partner. * **The Independent Directors:** There are only a few, including **Todd Bluedorn** (ex-CEO of Lennox) and **Tom Sweet** (ex-CFO of Dell). They are outnumbered. **The CEO (Jim Boyle):** He’s a lifer. Been with Medline since 1996. He’s not a hired gun brought in to dress it up for sale; he knows the plumbing of the business. Employee approval ratings are decent (\~77%), but not spectacular. Reading through employee reviews (Glassdoor, Reddit), a clear theme emerges: * **The Good:** "Supportive leaders" in some divisions; stable, recession-proof jobs; decent benefits. * **The Bad:** It’s a grinder. Warehouse roles have strict productivity quotas ("forced overtime" complaints). Sales roles are high-pressure. * **The Ugly:** There are allegations of a "toxic" culture in certain regional offices and complaints about a lack of formal training ("sink or swim"). * **Labor Risk:** There have been some rumblings about unionization and labor disputes in their distribution centers, which is a key risk for a logistics-heavy company. At the **IPO** the PE firms didn't sell everything, but they used the IPO proceeds (via the "Up-C" structure) to pay down debt and redeem *some* of their units. The PE firms still own **\~550 million units**. They *will* sell these eventually. Every time the stock pops, expect a secondary offering. This creates a massive supply overhang that will cap the stock price for the next 18-24 months. The underlying business itself is **moaty** (hybrid manufacturing plus distribution) where customers are locked into contracts, with high renewal rates. **Margins** are probably going to expand. The **ROIC / ROIIC are strong**, and there's very clear evidence of **operating leverage**. Overall it's a great company with a terrible public structure. I think it's best to wait until PE is fully done selling off their shares (\~799 million fully diluted shares; IPO was \~260) before looking at buying. So, maybe 12-24 months? Full post here - [https://thepursuitofcompounding.substack.com/p/medline?r=xy3ae](https://thepursuitofcompounding.substack.com/p/medline?r=xy3ae)